- GlobeNewswire•4 hours ago
WATERTOWN, Mass., Oct. 26, 2016-- Tetraphase Pharmaceuticals, Inc. today announced eight data presentations at IDWeek 2016, taking place October 26-30 in New Orleans, LA. Presentations will include information ...
- Zacks•9 days ago
Tetraphase Pharmaceuticals (TTPH) announced that it has begun dosing in the phase III IGNITE 4 study on its lead antibiotic candidate, eravacycline.
- GlobeNewswire•12 days agoTetraphase Pharmaceuticals Doses First Patient in IGNITE4 Phase 3 Clinical Trial of Eravacycline in cIAI
Top-line IGNITE4 Data Expected in 4 Q 2017. Results to Support NDA Filing for IV Eravacycline in cIAI. WATERTOWN, Mass., Oct. 14, 2016-- Tetraphase Pharmaceuticals, Inc. today announced dosing of the first ...
Tetraphase Pharmaceuticals, Inc. (TTPH)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||3.81 x 300|
|Ask||3.84 x 100|
|Day's Range||3.69 - 3.88|
|52wk Range||3.12 - 12.45|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.99|
|Avg Vol (3m)||349,293|
|Dividend & Yield||N/A (N/A)|